A Phase 3 interventional study of Rifaximin (Sandoz GmbH) tablet and Rifaximin (Xifaxan) in Travelers' Diarrhea, sponsored by Sandoz. Terminated at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-25.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.
Among the 19 studies testing rifaximin in Diarrhea, this one is the 18th largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 14th registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2016.
This study's enrollment of 28 is below the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 210 across the 19 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
13 studies in Diarrhea by Novartis: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 13 studies in Diarrhea by Novartis, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 11th registered.
Novartis’s Diarrhea studies by the year they started, since 1999.
1 of the studies testing rifaximin in Diarrhea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifaximin in Diarrhea, from their registry updates:
Among Novartis’s 13 in Diarrhea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea. Additionally both the generic and reference formulations were tested for superiority against a placebo tablet.
It was planned that 450 patients would be enrolled, but only 28 patients were randomized. Of these, 1 patient discontinued due to failure to meet the inclusion/exclusion criteria. The remaining 27 patients received study drug and 25 patients completed the study.
The study was terminated due to slow enrolment. The final analysis included only safety analysis in the Safety population, due to the low number of randomized patients. No efficacy analysis was performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
Drug: Rifaximin (Sandoz GmbH) tablet
Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
Drug: Rifaximin (Xifaxan)
Patients received placebo tablet 3 times per day for 3 days.
Drug: Placebo
200 mg tablet administered orally.
200 mg tablet administered orally
Also known as: Xifaxan®
Matching Placebo tablet administered orally
Clinical Cure Rate
Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.
Time frame: study day 5 +/- 1 day
Time to Last Unformed Stool
Time frame: within 5 study days
Proportion of Patients With Clinical Failure
Time frame: within 5 study days
Proportion of Patients With Improvement of Diarrheal Syndrome
Time frame: within 5 study days
Number of Unformed Stools
Time frame: within 5 study days
The Presence or Absence and Severity of Signs and Symptoms of Enteric Infection
Time frame: within 5 study days
Microbiological Cure Rate
Time frame: study day 5
| Milestone | Rifaximin | Xifaxan | Placebo |
|---|---|---|---|
| Started | 13 | 11 | 4 |
| Safety set | 12 | 11 | 4 |
| Completed | 11 | 11 | 3 |
| Not completed | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Did not meet inc./exc. criteria | 1 | 0 | 0 |
Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over up to day 5 +/- 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Xifaxan | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | Rifaximin | Xifaxan | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 1/12 | 3/11 | 0/4 |
| DizzinessNervous system disorders | 0/12 | 2/11 | 0/4 |
| Lacrimation increasedEye disorders | 0/12 | 1/11 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 0/12 | 1/11 | 0/4 |
| Medication errorInjury, poisoning and procedural complications | 0/12 | 1/11 | 0/4 |
| ConstipationGastrointestinal disorders | 1/12 | 0/11 | 0/4 |
Baseline characteristics was based on the safety analysis set.
| Age, Continuous(Years) | Rifaximin | Xifaxan | Placebo | Total |
|---|---|---|---|---|
| Mean | 36.3 ± 18.27 | 38.2 ± 18.69 | 35.8 ± 21.93 | 37.0 ± 18.22 |
| Sex: Female, Male(Participants) | Rifaximin | Xifaxan | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 7 | 1 | 13 |
| Male | 7 | 4 | 3 | 14 |
| Race (NIH/OMB)(Participants) | Rifaximin | Xifaxan | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 11 | 11 | 4 | 26 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in May 2017, 5 months.
Results were first posted in Mar 2019, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin